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Introduction: Collision tumors of adenocarcinoma and lymphoma in the gastrointestinal tract are
especially rare with few reported cases in literature. We report a unique case of a collision tumor and
perform a literature review.
Presentation of case: An 86-year-old patient with a history of rheumatoid arthritis on chronic
azathioprine and prednisone was found to have an invasive adenocarcinoma in the descending colon.
A large atypical lymphocytic inﬁltrate was found at the base of this lesion, which demonstrated CD20,
lambda and EBER positivity consistent with adenocarcinoma colliding with EBV-driven and lambda-
restricted large B-cell lymphoma.
Discussion: With this report, there are now ﬁfteen cases of this type of collision tumor although the
true incidence may be higher. Our case is unique among previous reports as the collision developed
within the setting of iatrogenic immunosuppression and tumor EBV positivity was demonstrated. The
pathogenesis is unknown, and diagnosis requires a high-degree of suspicion.
Conclusion: It is important to consider immunosuppression in a patient with adenocarcinoma, as
presence of atypical lymphoid cells may be indicative of lymphoma.
& 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Colorectal adenocarcinoma is one of the most common
neoplasms worldwide with more than half occurring in.12.002
hed by Elsevier Ltd. This is an op
/by-nc-nd/4.0/).
f Pathology, Saint Louis Uni-
is, MO 63104, United States.
6132.
(J.-P. Lai).developed regions [1]. In contrast, primary gastrointestinal
lymphoma is much more uncommon and deﬁned by extra-
nodal origin, normal white blood cell count, and lack of
involvement of peripheral or mediastinal lymph nodes, liver,
and spleen [2]. The vast majority are found in the stomach,
while prior studies in the United States showed from 8.5 to
10% arising from the large intestine [3–5]. Although rare, the
occurrence of primary colorectal adenocarcinoma with
primary lymphoma has been previously well-documented
in literature, [6] with the probability of synchronousen access article under the CC BY-NC-ND license
J.R. Yu et al.8occurrence estimated to be 2% [7]. Furthermore, synchro-
nous multiple primary tumors that are histologically distinct
and occur adjacently are even more rare [8]. These are
deﬁned as collision tumors. To date, only fourteen cases of
collisions of colorectal adenocarcinoma and colonic lym-
phoma have been previously reported. We describe the
clinicopathologic features of a patient with adenocarcinoma
of the colon colliding with EBV-driven large B-cell lymphoma
in the setting of chronic immunosuppression. A review of
literature is also performed.Figure 1 Gross examination: (A) a 6.6 3.2 cm2 soft, tan, exophy
6.5 4.5 cm2 ulcerated lesion in the descending colon with heape
examination (C–F): cecal tubulovillous adenoma with atypical lym
(C,  100; E,  400); low grade adenocarcinoma with a focus of h
inﬁltrates in the descending colon (D,  100; F,  400) (arrowhead2. Case report
An 86 year-old female presented with bloody diarrhea,
abdominal pain, and anemia. Past medical history was
signiﬁcant for rheumatoid arthritis treated with prednisone
and azathioprine. Physical exam was unremarkable and no
lymphadenopathy or organomegaly was noted. Laboratory
studies revealed white blood count 3500/mL and hemoglobin
8.6 g/dL. Colonoscopy showed mass lesions at the cecum
and splenic ﬂexure, and biopsies showed adenocarcinoma.tic mass with focal mucosal ulceration at the cecum and (B) a
d-up margins and necrotic appearing central area. Histologic
phocytic inﬁltrates at the base with increased mitotic activity
igh grade adenocarcinoma admixed with atypical lymphocytic
s indicate mitotic ﬁgures).
9Colon collision tumorsThe patient underwent right extended hemicolectomy to
the splenic ﬂexure. Gross examination revealed a surgical
specimen measuring 35 cm with a 6.6 3.2 cm2 soft, tan,
exophytic mass with focal mucosal ulceration at the cecum
(Figure 1A) grossly invading the bowel wall and a
6.5 4.5 cm2 ulcerated lesion in the descending colon
(Figure 1B) with heaped-up margins and necrotic appearing
central area that was grossly invading the subserosal fat.
The terminal ileum and appendix were unremarkable.
Histologic examination of the cecal mass showed tubulo-
villous adenoma (Figure 1C and E) with foci of high grade
dysplasia/adenocarcinoma in situ, while the descending
colon mass showed low grade adenocarcinoma with a focus
of high grade component (Figure 1D and F) invading through
the muscularis propria. Extensive moderate-to-large atypi-
cal lymphocytic inﬁltrates with increased mitotic activity
were noted at the base of both lesions (Figure 1C and F).
Immunohistochemistry of the lymphocytic inﬁltrates at both
sites were strongly and diffusely positive for CD20, positive
for lambda, and negative for kappa, while CD3 highlighted
some background mature T-cells (Figure 2A–C). EBV encod-
ing region in situ hybridization (EBER ISH) in the atypical B-
cells was positive (Figure 2D). Expression of DNA mismatch
repair proteins in the descending colon mass was found to
be intact.
The patient was discharged twelve days after resection. No
chemotherapy was initiated and the patient was instructed toFigure 2 Immunohistochemistry and in situ hybridization of the
(B) CD20 stains moderate-to-large atypical B-cells; (C) atypical lymp
(lower); and (D) EBER by in situ hybridization is positive in atypicadiscontinue prednisone and azathioprine. No recurrence was
noted six months after the procedure.3. Discussion
The pathogenesis of collision tumors has not been well-
established. Given the synchronous presentation, it is
difﬁcult to determine the temporal or causal relationship,
if any, between two primaries. Multiple primary tumors may
arise from a single factor including: environmental, genetic,
or immune system dysfunction [7]. A primary tumor may
cause cytokine dysregulation or decreased immune surveil-
lance to allow localized development of another primary. In
contrast, given the rarity of occurrence, it is possible that
collision tumors are merely an accidental event. Collision
tumors in the gastrointestinal tract are especially rare;
however, the number could be under reported. First,
deﬁnitions may vary, with some reports not categorizing it
as such. Second, in our literature review, we were unable to
verify reports in non-English literature. Lastly, collision
tumors are often difﬁcult to diagnose given the nonspeciﬁc
symptoms, and the presence of lymphoproliferative cells on
histology is often thought to be reactive changes.
To our knowledge, there are ﬁfteen cases of this type of
collision to date, including this report (Table 1) [9-22].
There is a male and elderly predominance at an average agececum mass: (A) CD3 stains some background mature T-cells;
hocytes are negative for kappa (upper), but positive for lambda
l B-cells (A–D,  200).
Table 1 Summary of ﬁfteen collision tumors of primary colorectal adenocarcinoma and primary gastrointestinal lymphoma.
Case Year Age/sex Signs and
symptoms
Tumor
location
Lymphoma
type
Immuno-
suppression
Treatment Follow-up
Cornes et al.
[9]
1960 63/M Tenesmus,
rectal bleeding,
weight loss
Rectum Lymphocytic
lymphosarcoma
NA Resection 1 year after resection: died of
uremia secondary to urinary
obstruction and enlarged
prostate
Aitani et al.
[10]
1987 59/M NA Transverse Diffuse large
B-cell
NA NA NA
Chazouilleres
et al. [11]
1990 56/F Tenesmus,
rectal bleeding,
weight loss
Rectum Follicular NA Resection followed by MACOP B 1 year after chemotherapy: no
recurrence noted
Mannweiler
et al. [12]
2003 73/M Diarrhea,
abdominal pain
Rectum Peripheral
T-cell
NA Resection NA
Padmanabhan
et al. [13]
2003 85/M Blood per
rectum,
dizziness
Cecum Mantle cell NA Resection 1 month after resection: died
of ruptured abdominal
aneurysm and myocardial
infarction
Minato et al.
[14]
2004 80/M Right lower
quadrant pain,
anemia
Ascending Diffuse large
B-cell
NA NA 5 months after diagnosis: died
of MRSA pneumonia
Eshra et al.
[15]
2010 67/M Intestinal
obstruction
Ascending Marginal zone NA Resection After resection: transferred to
another institution for further
adjuvant therapy
Sasaki et al.
[16]
2010 62/M Right lower
quadrant pain,
anemia
Cecum Follicular NA Resection with six cycles of CHOP+Rituximab for
lymphoma involving the duodenum
After initial chemotherapy:
began mFOLFOX6 for
metastatic adenocarcinoma to
liver
Tokoro et al.
[17]
2010 70/M Anemia, weight
loss, fecal
occult blood
Rectum Diffuse large
B-cell
NA Resection 23 days after resection and
second reconstruction: died of
aspiration pneumonia
Chang et al.
[18]
2011 86/M Tinnitus, visual
acuity
impairment
Cecum Diffuse large
B-cell
NA Rituximab, cyclophosphamide, vincristine,
prednisone for three cycles of 21 days, followed
by resection, followed by monthly vincristine
and prednisolone
16 months after initial
presentation: found to have
hepatic tumor but no
intervention performed
Devi et al.
[19]
2011 68/F Bleeding per
rectum
Ascending MALT NA Resection 2 months after resection: no
recurrence noted
Shigeno et al.
[20]
2011 76/F Ileocecal Diffuse large
B-cell
NA Resection
J.R.
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11Colon collision tumorsof 70.3 years. The majority of collisions arise in the cecum
or rectum, with eight arising from the right colon, one from
the transverse colon, and six from the left colon. The most
common lymphoma found was diffuse large B-cell lym-
phoma. Of note, most cases initially presented with signs
and symptoms suggestive of gastrointestinal disease and
were subsequently found to have lymphoma, except for
those described by Chang et al. [18] and Lin et al. [21].
In our case, the patient was found to have low grade
adenocarcinoma in the descending colon and tubulovillous
adenoma in the cecum both colliding with EBV-driven,
lambda-restricted large B-cell lymphoma. Analysis of DNA
mismatch repair proteins showed that a genetic or epige-
netic cause of the collision tumor was not likely. Two other
unique ﬁndings in this present case were not reported in our
review of previous cases. First, the patient developed a
collision tumor in the setting of iatrogenic immunodeﬁ-
ciency from chronic prednisone and azathioprine use.
Second, EBV positivity was demonstrated in tumor. Given
these ﬁndings, the development of large B-cell lymphoma in
this patient was determined to be driven by EBV, with
immunosuppression being the underlying cause.
We propose that immune dysregulation is the inciting
factor in collision tumors of the gastrointestinal tract. This
can be seen in the increased risk of lymphoma in patients
with inﬂammatory bowel disease on immunosuppression
[23-25]. The incidence of post-transplant lymphoprolifera-
tive disorders has been shown to increase with EBV viral
load [26]. EBV has also been detected in colorectal adeno-
carcinoma, suggesting it as a possible contributing factor
[27-28]. In our case, we postulate that iatrogenic immuno-
suppression allowed for proliferation of EBV, resulting in a
microenvironment susceptible to development of lymphoma
and subsequently adenocarcinoma. The presence of the
tubulovillous adenoma with underlying EBV positive large
B-cell lymphoma supports this mechanism, as it represents
an earlier stage in the adenoma-to-carcinoma sequence.
Given the rarity of occurrence, optimal treatment of
these collision tumors is unknown. Since collision tumors are
adjacent, it is likely that the initial management would
parallel the management of colorectal cancer. In the
majority of cases, the treatment approach involved resec-
tion and a primary lymphoma was subsequently identiﬁed on
histologic examination. In contrast, there were four cases in
which chemotherapy was part of the management. Two of
these four cases included chemotherapy because subse-
quent work-up following resection revealed lymphoma in
another location. Thus, further diagnostic studies may be
warranted with the ﬁnding of a collision tumor.4. Conclusion
Collision tumors of colorectal adenocarcinoma and lym-
phoma are rare, although the true incidence may be higher
than reported. The pathogenesis of collision tumors is
difﬁcult to elucidate given the uncommon occurrence.
Diagnosis requires a high-degree of suspicion as it may be
difﬁcult to distinguish primary lymphoma from benign
reactive changes. It is important to consider immunosup-
pression in a patient with adenocarcinoma, as a mixed
J.R. Yu et al.12pattern or atypical lymphoid cells may be indicative of
lymphoma.
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